Phase 2 trial: Evaluation of Treatmen... - Advanced Prostate...

Advanced Prostate Cancer

21,407 members26,796 posts

Phase 2 trial: Evaluation of Treatment Interruption After Response in mHSPC

Maxone73 profile image
0 Replies

"Patients are allowed to enrolle if they have a stable or falling prostate-specific antigen (PSA) level below 0.2 ng/mL and a castrate testosterone level under 50 ng/dL at baseline after having a PSA level of at least 5 ng/mL and a testosterone level of at least 150 ng/dL prior to the start of ADT. "

"This ongoing trial seeks to redefine management strategies for mHSPC by integrating periods of treatment interruption based on robust initial responses with the goal of improving QOL without affecting treatment outcomes."

Non inferiority would already be a great outcome, let's hope!

onclive.com/view/dr-choudhu...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Early Results from Transdermal Estrogen PATCH trial - 2

that have been castrated to a testosterone level < 50 ng/dL after 1 month of treatment. For...

Is there seasonality to testosterone levels?

of the ADT. * Aug 18 2023: PSA is 0.09, Testosterone is 3.3 nmol/l (95.2 ng/dL), Testosterone...

Phase 1 trial participation Nurix NX-1607

I have not been on any treatment since I stopped Docetaxel chemo last year except Prostap injections

Does Erectile function come back after radiation treatment+brachytherapy+2 year ADT?

after such a treatment? PSA was <0.1 and testosterone was <20 while on ADT. Finished ADT in Sept...

PSA drop Testosterone jump 21days on Casodex b4 Lupron last week

effects yet. Question? Last weeks PSA and Testosterone labs surprised me. PSA Total Ser QN 8.566...